A 26-week open-label study of quetiapine in children with conduct disorder.

Department of Psychiatry, University Hospitals of Cleveland/Case Western Reserve University, Cleveland, Ohio 44106-5080, USA.
Journal of Child and Adolescent Psychopharmacology (Impact Factor: 3.07). 03/2007; 17(1):1-9. DOI: 10.1089/cap.2006.0027
Source: PubMed

ABSTRACT The aim of this study was to describe the long-term safety and effectiveness of quetiapine in conduct disorder (CD).
This was an 18-week outpatient follow-up study of an acute trial that enrolled aggressive children ages 6-12 years with a primary diagnosis of CD. To be enrolled into this study, subjects had to have successfully completed participation in the initial 8-week, open-label, outpatient quetiapine trial. Psychometric measures included the Rating of Aggression Against People and/or Property Scale (RAAPP), the Nisonger Child Behavior Rating Form (NCBRF), the Conners' Parent Rating Scale (CPRS-48), the Clinical Global Impressions Scale of Severity (CGI-S), and the Children's Global Assessment Scale.
Nine males with a mean age of 8.9 (SD = 1.2) years were treated. The median quetiapine dose at end of study was 150 mg/day (range 75-350). Mean psychometric scores did not change substantively from baseline. No patients experienced extrapyramidal side effects. Three subjects discontinued due to study nonadherence. No patients discontinued treatment due to an adverse event.
These preliminary data suggest that quetiapine might be a generally safe and effective maintenance treatment for aggressive children with CD who initially respond to an acute therapeutic trial of quetiapine. More research is needed to confirm or refute these initial findings.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This systematic review examines treatment guidelines, efficacy/effectiveness, and tolerability regarding the use of antipsychotics concurrently with psychostimulants in treating aggression and hyperactivity in children and adolescents. Articles examining the concurrent use of antipsychotics and psychostimulants to treat comorbid attention deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs) were identified and their results were summarized and critically analyzed. Antipsychotic and stimulant combination therapy is recommended by some guidelines, but only as a third-line treatment following stimulant monotherapy and stimulants combined with behavioral interventions to treat aggression in patients with ADHD. Some studies suggest efficacy/effectiveness for an antipsychotic and stimulant combination in the treatment of aggression and hyperactivity in children and adolescents. However, the data do not clearly demonstrate superiority compared to antipsychotic or psychostimulant monotherapy. Most studies were performed over short time periods, several lacked blinding, few studies used any placebo control, and no comparisons were made with behavioral interventions. There are concerns about the tolerability of combination therapy, but data do not suggest significantly worse adverse effects for combination compared to either antipsychotic or stimulant monotherapy. Conversely, and contrary to speculation, use of a stimulant does not significantly reduce metabolic effects of antipsychotics. Combination treatment with antipsychotics and psychostimulants is used frequently, and increasingly more often. Few studies have directly examined this combination for the treatment of ADHD and DBDs. Further studies are necessary to confirm the efficacy and tolerability of the concurrent use of antipsychotics and psychostimulants in children and adolescents.
    Current Psychiatry Reports 05/2013; 15(5):355. · 3.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aggressives Verhalten kann isoliert oder als Begleit-beziehungsweise Folge-Symptom bei verschiedenen psychiatrischen Erkrankungen auftreten. Aggressionen können gegen sich selbst (Selbstverletzungen, Parasuizidalität, Suizidalität) oder gegen andere gerichtet sein. Aggressives Verhalten kann Folge einer Psychopathie sein (z.B. antisoziale Persönlichkeitsstörung), einer emotionalen Dysregulation (z.B. Borderline-Persönlichkeitsstörung), einer Störung der Impulskontrolle (ADHS), einer kognitiven Einschränkung (primäre Intelligenzminderung oder sekundäre Defizite z.B. bei Psychose) oder einer Traumatisierung bzw. Belastung (z.B. posttraumatische Belastungsstörung, Anpassungsstörungen; Siever, 2008). Dennoch konnte impulsiv-aggressives Verhalten (impulsive aggression) als valides diagnostisches Konstrukt identifiziert werden, welches über kategoriale Störungsbilder hinweg gleichförmig auftreten kann (Jensen et al., 2007).
    12/2008: pages 333-344;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Method: An open, naturalistic observational study design was used, in which a sample of seven boys between 10 and 14 years of age was assessed over 26 weeks. Results: The subjects were all diagnosed with conduct disorder (CD) and exhibited high levels of aggression that were refractory to psychosocial approaches (parent counseling, school counseling, and psychotherapy) and to more than three pharmacological treatments. Levels of aggression, side effects, and hematological parameters were evaluated weekly. Clinical response was evaluated using the standardized instruments Clinical Global Impressions (CGI) and Child Behavior Check List (CBCL) 6-18 before starting medication and after 26 weeks. Conclusion: We observed good tolerability of clozapine in doses from 100 to 600 mg/day with no significant side effects or hematological changes. The CGI and CBCL 6-18 scales indicated that clozapine led to a marked control of symptoms.
    Journal of child and adolescent psychopharmacology 01/2013; · 2.59 Impact Factor